Clinically Sound Investor
Dec. 18, 2015, 9:16 AM
- Mallinckrodt (NYSE:MNK) acquires three hemostasis products from The Medicines Company (NASDAQ:MDCO), RECOTHROM Thrombin topical (Recombinant), PreveLeak and RAPLIXA (fibrin sealant), for up to $410M.
- Under the terms of the transaction, MDCO will receive an upfront payment of ~$175M (including inventory) and milestones of up to $235M.
- MDCO President and CFO Glenn Sblendorio says, "This deal will deliver a substantial amount of non-dilutive capital to the company so that we can continue to focus on core programs including our research and development for PCSK9 inhibition and continue to unlock shareholder value."
Dec. 4, 2013, 6:59 AM
- Medicines Company (MDCO) has acquired Rempex Pharmaceuticals, a developer of treatments for multi-drug resistant infections in hospitals.
- Medicines paid $140M upfront and will pay another $334M in milestones.
- Rempex's products include Carbavance, which has completed Phase 1 dose-escalation studies in normal subjects and is expected to enter registration trials next year.
- Another pharmaceutical is Minocin IV, which has already been approved. (PR)
Aug. 5, 2013, 5:19 PM
- The Medicines Company (MDCO) says the dry powder topical fibrinogen and thrombin formulation Fibrocaps met "all primary and secondary hemostasis efficacy endpoints" in a pivotal Phase 3 trial.
- The results should support a BLA in the U.S. and an MAA in Europe.
- MDCO previously agreed to purchase all of the outstanding equity of Fibrocaps' developer ProFibrix upon review of the Phase 3 data. That transaction was completed today for $90M. ProFibrix shareholders are entitled to an additional $140M in milestone payments tied to sales and regulatory outcomes.
- Assuming regulatory approval, MDCO sees peak Fibrocaps sales of $300M. (PR)
- MDCO +2.45% AH.
Jun. 4, 2013, 3:16 PM
The Medicines Company (MDCO -1.4%) agrees to buy all of the outstanding capital stock of ProFibrix, subject to the company's satisfactory review of the pending Phase 3 clinical trial results of ProFibrix's lead biologic Fibrocaps. Under the terms of the agreement, MDCO will pay ProFibrix a $10M upfront option payment. If the company is satisfied with the trial results of the trial and decides to proceed, it will purchase all of the outstanding capital stock of ProFibrix at closing.| Jun. 4, 2013, 3:16 PM
Dec. 12, 2012, 12:47 PM
As a condition of Medicines Company's (MDCO +1.9%) acquisition of Incline Therapeutics, Cadence Pharmaceuticals (CADX +4.9%) has agreed to terminate its exclusive option to acquire Incline. Upon MDCO's closing of the deal, CADX will receive around $13M in termination fees and roughly $1.5M for its Incline stake as well as a pro-rated share of future milestone payments.| Dec. 12, 2012, 12:47 PM
Dec. 12, 2012, 12:37 PM
Medicines Company (MDCO +1.9%) moves up today after agreeing to acquire privately held Incline Therapeutics for $185M plus potential milestone payments. The acquisition gives MDCO access to the development of a disposable and needleless patient-controlled analgesia system for postoperative pain management in hospitals. Additionally, the company also reached a licensing agreement with Bristol-Myers Squibb (BMY +0.6%) on its Recothrom topical treatment to control bleeding during surgery.| Dec. 12, 2012, 12:37 PM